186 related articles for article (PubMed ID: 21996594)
1. Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.
Koiou E; Tziomalos K; Dinas K; Katsikis I; Kandaraki EA; Tsourdi E; Mavridis S; Panidis D
Endocr J; 2012; 59(1):21-9. PubMed ID: 21996594
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
Panidis D; Tziomalos K; Misichronis G; Papadakis E; Betsas G; Katsikis I; Macut D
Hum Reprod; 2012 Feb; 27(2):541-9. PubMed ID: 22144419
[TBL] [Abstract][Full Text] [Related]
3. Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes.
Aziz M; Sidelmann JJ; Faber J; Wissing ML; Naver KV; Mikkelsen AL; Nilas L; Skouby SO
Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1082-9. PubMed ID: 26123797
[TBL] [Abstract][Full Text] [Related]
4. Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system.
Sills ES; Drews CD; Perloe M; Tucker MJ; Kaplan CR; Palermo GD
Gynecol Endocrinol; 2003 Jun; 17(3):231-7. PubMed ID: 12857431
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome.
Koiou E; Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Panidis D
Gynecol Endocrinol; 2013 Mar; 29(3):250-3. PubMed ID: 23216335
[TBL] [Abstract][Full Text] [Related]
6. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.
Durmus U; Duran C; Ecirli S
J Endocrinol Invest; 2017 May; 40(5):487-497. PubMed ID: 27838846
[TBL] [Abstract][Full Text] [Related]
7. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
[TBL] [Abstract][Full Text] [Related]
8. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?
Orio F; Palomba S; Cascella T; Tauchmanovà L; Nardo LG; Di Biase S; Labella D; Russo T; Savastano S; Tolino A; Zullo F; Colao A; Lombardi G
Reprod Biomed Online; 2004 Nov; 9(5):505-10. PubMed ID: 15588467
[TBL] [Abstract][Full Text] [Related]
9. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome.
Ujvari D; Hulchiy M; Calaby A; Nybacka Å; Byström B; Hirschberg AL
Hum Reprod; 2014 Jul; 29(7):1526-35. PubMed ID: 24842895
[TBL] [Abstract][Full Text] [Related]
10. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.
Sampson M; Kong C; Patel A; Unwin R; Jacobs HS
Clin Endocrinol (Oxf); 1996 Nov; 45(5):623-9. PubMed ID: 8977761
[TBL] [Abstract][Full Text] [Related]
11. Plasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome.
Koiou E; Tziomalos K; Katsikis I; Dinas K; Tsourdi EA; Kandaraki EA; Delkos D; Papadakis E; Panidis D
Hormones (Athens); 2012; 11(1):77-85. PubMed ID: 22450347
[TBL] [Abstract][Full Text] [Related]
12. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels.
Piouka A; Farmakiotis D; Katsikis I; Macut D; Gerou S; Panidis D
Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E238-43. PubMed ID: 18957615
[TBL] [Abstract][Full Text] [Related]
13. Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.
Panidis D; Tziomalos K; Macut D; Delkos D; Betsas G; Misichronis G; Katsikis I
Fertil Steril; 2012 Feb; 97(2):494-500. PubMed ID: 22192350
[TBL] [Abstract][Full Text] [Related]
14. The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria.
Koiou E; Dinas K; Tziomalos K; Toulis K; Kandaraki EA; Kalaitzakis E; Katsikis I; Panidis D
Obes Facts; 2011; 4(2):145-50. PubMed ID: 21577021
[TBL] [Abstract][Full Text] [Related]
15. Psoriasis and polycystic ovary syndrome: a new link in different phenotypes.
Moro F; Tropea A; Scarinci E; Federico A; De Simone C; Caldarola G; Leoncini E; Boccia S; Lanzone A; Apa R
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():101-5. PubMed ID: 26115053
[TBL] [Abstract][Full Text] [Related]
16. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
Koiou E; Tziomalos K; Katsikis I; Delkos D; Tsourdi EA; Panidis D
Hormones (Athens); 2013; 12(4):559-66. PubMed ID: 24457404
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
18. Vascular function in the diagnostic categories of polycystic ovary syndrome.
Moran LJ; Cameron JD; Strauss BJ; Teede HJ
Hum Reprod; 2011 Aug; 26(8):2192-9. PubMed ID: 21616917
[TBL] [Abstract][Full Text] [Related]
19. The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome.
Zhang L; Fang X; Li L; Liu R; Zhang C; Liu H; Tan M; Yang G
J Endocrinol Invest; 2018 Dec; 41(12):1401-1407. PubMed ID: 29785700
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity.
Cassar S; Teede HJ; Harrison CL; Joham AE; Moran LJ; Stepto NK
Clin Endocrinol (Oxf); 2015 Jul; 83(1):50-8. PubMed ID: 25262763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
